Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Abbott
>
Abbott Neuromodulation
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="anonymous, post: 6216398"]9% decline in sales in Q1 year over year - in a market where the competitors are growing at a double-digit rate... The chickens have finally come home to roost and the Abbott neuromodulation division is paying a huge price for the arrogance in upper management. You would think that changes in the senior management group are imminent after 3 dismal quarters, but Miles White is between a rock and a hard place. He can't fire Keith Boettiger, as he does not know anything about neuromodulation. At the same time, he might have an investor revolt on his hands if he does not get more out of a division where market growth is above 10% per year. The Q1 '19 results will probably force his hand. Or hopefully - not sure I want stock in a company where executive leadership can't make simple calls like this. The rot starts at the top.[/QUOTE]</p><p><br /></p>
[QUOTE="anonymous, post: 6216398"]9% decline in sales in Q1 year over year - in a market where the competitors are growing at a double-digit rate... The chickens have finally come home to roost and the Abbott neuromodulation division is paying a huge price for the arrogance in upper management. You would think that changes in the senior management group are imminent after 3 dismal quarters, but Miles White is between a rock and a hard place. He can't fire Keith Boettiger, as he does not know anything about neuromodulation. At the same time, he might have an investor revolt on his hands if he does not get more out of a division where market growth is above 10% per year. The Q1 '19 results will probably force his hand. Or hopefully - not sure I want stock in a company where executive leadership can't make simple calls like this. The rot starts at the top.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Abbott
>
Abbott Neuromodulation
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Abbott
>
Abbott Neuromodulation
>